Cost-effectiveness of targeted screening for hepatitis C in the Netherlands

Epidemiology and Infection

Volumn 140, Issue 1, 2012, Pages 58-69

  Helsper, C W ^a   Borkent Raven, B A ^a   De Wit, N J ^a   Van Essen, G A ^a   Bonten, M J M ^a   Hoepelman, A I M ^a   Janssen, M P ^a   De Wit, G A ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cost effectiveness study; hepatitis (general); hepatitis C; prevention; public health emerging infections

Indexed keywords

HEPATITIS C VACCINE;

ARTICLE; ATTITUDE TO HEALTH; CASE FINDING; COST EFFECTIVENESS ANALYSIS; DRUG ABUSE; FUNDING; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MASS SCREENING; MATHEMATICAL MODEL; NETHERLANDS; PRIMARY MEDICAL CARE; PUBLIC HEALTH SERVICE; SENSITIVITY ANALYSIS; VIRUS CARRIER;

COMMUNICABLE DISEASES, EMERGING; COST-BENEFIT ANALYSIS; DRUG USERS; HEALTH PROMOTION; HEPATITIS C; HUMANS; MASS SCREENING; MULTIVARIATE ANALYSIS; NETHERLANDS; PILOT PROJECTS;

EID: 82455175310     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811000112     Document Type: Article

References (40)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005; 5: 558-567. (Pubitemid 41196755)
2. World Health Organisation. Hepatitis C: global prevalence. Weekly Epidemiological Record 1997; 72: 341-344.
3. Lauer GM, Walker BD. Hepatitis C virus infection. New England Journal of Medicine 2001; 345: 41-52. (Pubitemid 32634271)
4. Manns MP, et al. The way forward in HCV treatmentfinding the right path. Nature Reviews Drug Discovery 2007; 6: 991-1000. (Pubitemid 350201789)
5. Thompson-Coon J, et al. Case finding for hepatitis C in primary care: a cost utility analysis. Family Practice 2006; 23: 393-406.
6. Foster GR, et al. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. British Medical Journal 1997; 315: 453-458. (Pubitemid 27348463)
7. Slavenburg S, et al. Prevalence of hepatitis C in the general population in the Netherlands. Netherlands Journal of Medicine 2008; 66: 13-17. (Pubitemid 351188284)
8. Kretzschmar MEE. The prevalence of hepatitis C in the Netherlands [in Dutch]. Bilthoven, the Netherlands, National Institute of Public Health and the Environment, 2004; publication number VWS-IGZ 2004/02 - Project V/210041.
9. Kok A, et al. Hepatitis C in the Netherlands: sparse data on the current prevalence and the necessity for epidemiological studies and innovative methods for detecting infected individuals [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2007; 151: 2367-2371. (Pubitemid 350057322)
10. Health Council of the Netherlands. Committee on hepatitis C. Detection and treatment of people with hepatitis C. Rijswijk: Health Council of the Netherlands, 1997; publication no. 1997/19.
11. de Vries MJ, te Rijdt B, van Nieuwkerk CM. Transmission of hepatitis C genotypes in the Netherlands amongst recently genotyped patients. Netherlands Journal of Medicine 2008; 66: 40-41. (Pubitemid 351188291)
12. Frank C, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891. (Pubitemid 30137669)
13. Meltzer MI. Introduction to health economics for physicians. Lancet 2001; 358: 993-998. (Pubitemid 32913530)
14. Helsper CW, et al. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Family Practice 2010; 27: 328-332.
15. Laar van MW, et al. National drug monitor 2007. Utrecht, The Netherlands, Trimbos Institute. WODC research and documentation centre, 2008, publication no. AF0809.
16. Veen van der C, Hoogenboezem G, Breemer J. Education campaign aimed at hard drug users. Results of a pilot study [in Dutch]. Verslaving: Tijdschrift over Verslavingsproblematiek 2009; 5: 61-71.
17. Siebert U, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-432. (Pubitemid 36250066)
18. StatLine - Statistics Netherlands. (http://statline.cbs. nl/StatWeb/publication/?VW=T&DM=SLNL&PA= 60020&LA=NL) [in Dutch]. Accessed 6 October 2006.
19. Smyth B, Fan J, Hser YI. Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. Journal of Addictive Diseases 2006; 25: 37-47. (Pubitemid 44707288)
20. Organisation for Economic Cooperation and Development (OECD). Health Data 2007 (CD-ROM), 2007.
21. Breemer J, et al. Pre- and post-test counselling of hepatitis C, HIV and hepatitis B. Test protocol. Project active testing in addiction care and social shelter [in Dutch]. Rotterdam, The Netherlands: GGD Rotterdam-Rijnmond 2007.
22. Veldt B. Long-term clinical outcome of treatment for chronic hepatitis C [dissertation]. Rotterdam, the Netherlands: Rotterdam University, 2008, 52 pp.
23. Rodenburg-van Dieten H. Guidelines for farmacoeconomic research [in Dutch]. Diemen, the Netherlands: College voor Zorgverzekeringen, 2006, publication number FARM 24088606.
24. Op de Coul E, Bosman A, van de Laar M. Surveillance of hepatitis C in the Netherlands, 1992-2002 [in Dutch]. Infectieziekten Bulletin 2003; 9: 323-328.
25. de Jong DJ, et al. Referral of hepatitis C virus seropositive patients in primary care in the Netherlands. Netherlands Journal of Medicine 2008; 66: 42-43.
26. The Health Care Insurance Board (CVZ). Farmacotherapeutic Compass database (http://www.fk.cvz.nl/). Accessed 8 July 2008.
27. Statistics Netherlands (CBS). CBS table: Population per region subdivided to country and gender Database (http://statline.cbs.nl/StatWeb/). Accessed 1 January 2006.
28. Berg van den M, et al. Cost-effectiveness of prevention: opportunities for public health policy in the Netherlands [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2008;152:1329-1334.
29. Castelnuovo E, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technology Assessment 2006; 10: xiii-iv, ix-xii, 1-93.
30. Stein K, et al. Screening for hepatitis C in injecting drug users: a cost utility analysis. Journal of Public Health (Oxford) 2004; 26: 61-71. (Pubitemid 38788605)
31. Sroczynski G, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. European Journal of Public Health 2009; 19: 245-253.
32. Statistics Netherlands (CBS). CBS table: Population of the Netherlands on first of January; age, country of birth and region (http://statline.cbs.nl/ StatWeb/). Accessed 16 September 2009.
33. Wilson JMG, Jungner G. Principles and practice of mass screening for disease. Boletn de la Oficina Sanitaria Panamericana 1968; 65: 281-393.
34. Andermann A, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization 2008; 86: 317-319. (Pubitemid 351521860)
35. Veldhuijzen IK, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138: 522-530.
36. Paltiel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. New England Journal of Medicine 2005; 352: 586-595. (Pubitemid 40204671)
37. Bozzette SA. Routine screening for HIV infectiontimely and cost-effective. New England Journal of Medicine 2005; 352: 620-621. (Pubitemid 40204676)
38. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clinical Infectious Diseases 2009; 48: 313-320.
39. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5: 610-622.
40. Statistics Netherlands (CBS). CBS table: immigration and emigration (http://statline.cbs.nl/StatWeb/). Accessed 16 September 2009.